Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 7/20 | 0.69 |
| ▸ | MAOA | P21397 | 5/20 | 0.69 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.69 |
| ▸ | SDHA | P31040 | 2/20 | 0.69 |
| ▸ | LMNA | P02545 | 1/20 | 0.69 |
| ▸ | CALML3 | P27482 | 1/20 | 0.69 |
| ▸ | F10 | P00742 | 7/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10151558 | 0.92 | MAOB (0.80) | MAOBMAOAPTGS1SDHALMNA | |
| SCHEMBL5412018 | 0.91 | MAOB (0.73) | MAOBMAOAPTGS1SDHALMNA | |
| SCHEMBL8577685 | 0.91 | MAOB (0.73) | MAOBMAOAPTGS1SDHALMNA | |
| SCHEMBL10151452 | 0.89 | MAOB (0.62) | MAOBMAOAPTGS1SDHALMNA | |
| SCHEMBL13174832 | 0.89 | MAOB (0.55) | MAOBMAOAPTGS1SDHALMNA | |
| SCHEMBL10151494 | 0.87 | MAOB (0.75) | MAOBMAOAPTGS1SDHALMNA | |
| SCHEMBL10151444 | 0.86 | MAOB (0.66) | MAOBMAOAPTGS1SDHALMNA | |
| SCHEMBL2088028 | 0.85 | MAOB (0.65) | MAOBMAOAPTGS1SDHALMNA | |
| SCHEMBL14577593 | 0.85 | MAOB (0.78) | MAOBMAOAPTGS1SDHALMNA | |
| SCHEMBL2088162 | 0.85 | MAOB (0.64) | MAOBMAOAPTGS1SDHALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2009012-B1 | NOVEL COMPOUND HAVING HETEROCYCLIC RING | RES FOUND ITSUU LAB (JP) | 2014-06-25 | — | — | EP | disclosed |
| US-8530646-B2 | Oxazolidinone derivative having 7-membered hetero ring | RESEARCH FOUNDATION ITSUU LABORATORY (JP) | 2013-09-10 | — | — | US | disclosed |
| US-8530646-B2 | Oxazolidinone derivative having 7-membered hetero ring | RESEARCH FOUNDATION ITSUU LABORATORY (JP) | 2013-09-10 | — | — | US | disclosed |
| US-20120208997-A1 | NOVEL COMPOUND HAVING HETEROCYCLIC RING | SUZUKI HIDEYUKI (JP) | 2012-08-16 | — | — | US | disclosed |
| US-8148362-B2 | Compound having heterocyclic ring | RESEARCH FOUNDATION ITSUU LABORATORY (JP) | 2012-04-03 | — | — | US | disclosed |
| US-8148362-B2 | Compound having heterocyclic ring | RESEARCH FOUNDATION ITSUU LABORATORY (JP) | 2012-04-03 | — | — | US | disclosed |
| US-20100256355-A1 | OXAZOLIDINONE DERIVATIVE HAVING 7-MEMBERED HETERO RING | Research Foundation ITSUU Laboratory and Shionogi & Co., Ltd. | 2010-10-07 | — | — | US | disclosed |
| US-20090299059-A1 | Novel Compound Having Heterocyclic Ring | RESEARCH FOUNDATION ITSUU LABORATORY (JP) | 2009-12-03 | — | — | US | disclosed |
| US-20090299059-A1 | Novel Compound Having Heterocyclic Ring | RESEARCH FOUNDATION ITSUU LABORATORY (JP) | 2009-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090299059-A1 | Novel Compound Having Heterocyclic Ring | NR0B2, NR2C2, NR0B1 | MAOB 2611/4885MAOA 2965/4885PTGS1 4218/4885 |
| US-20120208997-A1 | NOVEL COMPOUND HAVING HETEROCYCLIC RING | OXA1L, MRPL21, TOP1 | MAOB 1404/4885MAOA 1563/4885PTGS1 1758/4885 |
| US-20100256355-A1 | OXAZOLIDINONE DERIVATIVE HAVING 7-MEMBERED HETERO RING | NR0B2, NR0B1, NR2C2 | MAOB 2570/4885MAOA 2966/4885PTGS1 4086/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.